FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 under
the
Securities Exchange Act of 1934
For the month ended
February, 2013
ICON plc
(Registrant's
name)
0-29714
(Commission file number)
South
County Business Park, Leopardstown, Dublin 18, Ireland
(Address of
principal executive offices)
Brendan Brennan, CFO
South County
Business Park Leopardstown, Dublin 18, Ireland.
Brendan.Brennan@iconplc.com
0011-353-1-291-2000
(Name,
telephone number, email and/or facsmile number and address of Company
contact person)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Yes___X___ No_______
Indicate by check mark whether the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1):
Yes______ No___X___
Indicate by check mark whether the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7):
Yes______ No___X___
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes_______ No___X___
If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b):82 N/A
EXHIBIT LIST
|
Exhibit |
Description |
||
|
99.1 |
ICON plc Press Release issued February 21, 2013 |
||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ICON plc |
||
|
|
||
| Date: |
February 21, 2013 |
/s/ Brendan Brennan |
|
Brendan Brennan |
||
|
Chief Financial Officer |
Exhibit 99.1
ICON Announces Appointment of Professor William Hall to Board of Directors
DUBLIN--(BUSINESS WIRE)--February 21, 2013--ICON plc, (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the appointment of Professor William Hall as a non-executive director.
A renowned expert in infectious diseases and virology, Professor Hall is Chair of Medical Microbiology and Director of the Centre for Research in Infectious Diseases at University College Dublin’s (UCD) School of Medicine and Medical Science. He is also a director of UCD’s National Virus Reference Laboratory and is a consultant microbiologist at St. Vincent’s University Hospital Dublin. Professor Hall also serves as a consultant to the Minister of Heath and Children in the Republic of Ireland, providing input on a number of topics including influenza pandemic preparedness and bioterrorism.
Prior to his tenure at UCD, Professor Hall was Professor and Head of the Laboratory of Medical Virology, Senior Physician and Director of the Clinical Research Centre at the Rockefeller University in New York. He has also served as an Assistant and Associate Professor of Medicine at Cornell University.
Professor Hall is a board member of The Atlantic Philanthropies and is a co-founder of the Global Virus Network.
“We are delighted to welcome Professor Hall to the ICON Board,” commented Chairman, Mr. Thomas Lynch. “His knowledge and expertise in virology and infectious diseases, coupled with his international research collaborations in these fields will complement the strengths and talents of our existing board members.”
The information contained in this release is as of 21st February 2013. The statements made in this press release may contain forward-looking statements that involve a number of risks and uncertainties. A description of risks and uncertainties relating to ICON and its business can be found in ICON’s Annual Report for the fiscal year ended December 31, 2011 and in the forms filed with the US Securities and Exchange Commission, including the Forms 20-F, F-1, S-8 and F-3. ICON disclaims any intent or obligation to update these forward-looking statements.
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 79 locations in 37 countries and has approximately 10,045 employees. Further information is available at www.iconplc.com.
Source: ICON plc
ICON/ICLR-F
CONTACT:
ICON plc
Investor Relations 1-888-381-7923
or
Brendan
Brennan Chief Financial Officer
+ 353 –1-291-2000
or
Sam
Farthing VP Investor Relations
+ 353 –1-291-2000
or
Simon
Holmes EVP Investor Relations and Corporate Development
+ 353
–1-291-2000